Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period

NCT00096473 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00096473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2001
Completion date
September 30, 2005
Enrollment
229 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, dementia